Press releases, workshop summaries, and editorials

The 2024 NINDS Parkinson’s Disease Biomarkers Program (PDBP) Annual Meeting provided a forum for participating scientists and stakeholders to discuss recent progress and emergent opportunities in Parkinson’s disease (PD), Lewy body dementia (LBD), and related parkinsonism biomarkers research. 

The 2023 NINDS PDBP Annual Meeting (hybrid) was held on September 21, 2023. Principal investigators, clinical coordinators and data management experts from each PDBP project, persons with lived experience, as well as representatives from the National Institutes of Health (NIH) and PD nonprofit organizations met to discuss biomarkers research and progress made over the last twelve months.

The 2021 PDBP Annual Consortium Meeting was held virtually on August 16-17, 2021. Principal Investigators (PIs), clinical coordinators and data management experts from each PDBP project, PDBP participants and caregivers, as well as representatives from the National Institutes of Health (NIH), PD nonprofit organizations, and the pharmaceutical industry met to discuss progress over the last twelve months in addition to current and future plans for the program.

The PDBP Annual Consortium Meeting was held as a virtual meeting on August 17-18, 2020.  The meeting provided a forum for participating scientists and stakeholders to discuss recent progress and emergent opportunities in Parkinson's disease (PD), Lewy body dementia (LBD) and related Parkinsonisms biomarker research. 

The PDBP Annual Consortium Meeting was held August 12-13, 2019 in Rockville, MD.  Principal investigators (PIs), clinical and data management experts from each PDBP project, and representatives from the  NIH, PD nonprofit organizations , and the pharmaceutical industry met to discuss progress over the last twelve months in addition to current and future plans for the program.

Shared platform to catalyze research collaboration toward biomarker discovery to advance the development disease therapies

The Accelerating Medicines Partnership (AMP) program for Parkinson’s disease (PD) has launched a data portal to provide de-identified information collected from 4,298 PD patients and healthy controls to researchers working to develop effective therapies for the disease. The portal enables researchers to study complex data sets and perform genome-wide analyses at a scale previously impossible.